NASDAQ$SEER

Seer Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Seer reported Q1 2025 revenue of $4.2 million, driven by strong product and service sales, and reiterated its full-year revenue guidance.

Seer achieved $4.2 million in revenue during Q1 2025, reflecting 37% year-over-year growth. Improved gross profit of $2.1 million and a stable cash position of $285 million highlighted the quarter, though net losses persisted at $19.9 million.

  • Revenue grew 37% YoY to $4.2 million in Q1 2025
  • Gross margin improved to 49% with gross profit of $2.1 million
  • Operating expenses declined 14% due to lower stock-based compensation
  • Cash, cash equivalents, and investments stood at $285 million at quarter-end

Headline financials

Total Revenue

$4.21M

Previous: $3.07M+37.1%
EPS (adj)

-$0.34

Previous: -$0.32-6.3%
Gross Margin

49.0%

No prior period
Capital Expenditures

-$654K

Previous: -$754K+13.3%
Net Income

-$19.9M

Previous: -$20.7M+3.5%
Operating Income

-$20.7M

Previous: -$25.2M+17.7%
Gross Profit

$2.06M

Previous: $1.36M+51.4%

Revenue & EPS history

Seer · Revenue · Quarterly

$4.21M

Q1 2025+37.1%vs Q1 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Seer · $3.81M total across 3 segments · Q3 2023

  • Product Revenue
    $1.85M-28.1%
  • Related Party Revenue
    $1.43M+8.6%
  • Service Revenue
    $536K-21.8%

Forward guidance

Seer reiterated its full-year 2025 revenue guidance of $17–18 million, aiming for 24% growth at the midpoint. The company remains confident in long-term market adoption of its Proteograph platform despite macroeconomic volatility.

Tailwinds

  • Full-year 2025 revenue guidance reaffirmed at $17–18 million
  • Signed major customer contract for 10,000-sample study
  • Shipped as many instruments in Q1 2025 as all of 2024
  • Strong validation through third-party publications and preprints
  • Operating expenses decreased due to reduced stock-based comp

Headwinds

  • Net loss of $19.9 million remains significant
  • Continued macroeconomic headwinds for life sciences industry
  • Gross margin below 50%, limiting profitability
  • Reduction in related party revenue YoY
  • Decline in interest income compared to prior year

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-1.1%

Avg return

Earnings day

-3.4%

Avg return

5 days after

-1.3%

Avg return

30 days after

38%

9 / 24 earnings

Positive

+39.4%

Q4 2022

Best reaction

-33.3%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.7%-7.7%
Q4 2025-17.4%-11.1%-20.2%
Q3 2025-1.4%-4.6%-13.4%
Q1 2025+10.0%+7.8%+7.8%
Q4 2024-4.5%-7.3%-20.9%
Q3 2024+9.4%+10.3%+22.2%
Q2 2024+0.0%-1.2%-4.7%
Q1 2024-6.8%-10.0%-21.7%
Q4 2023+1.1%+6.1%+5.6%
Q3 2023-7.4%-11.4%-5.1%
Q2 2023-33.3%-40.6%-43.6%
Q1 2023-2.2%-11.2%+33.7%
Q4 2022+39.4%+20.8%-1.3%
Q3 2022-3.4%+22.0%-7.4%
Q2 2022+19.5%+6.9%-12.4%
Q1 2022+5.5%-5.7%+5.7%
Q4 2021-6.6%-15.3%+1.8%
Q3 2020-11.4%-13.5%-31.0%
Q3 2021-11.4%-13.5%-31.0%
Q2 2021+8.1%-0.8%+44.5%
Q2 2020+8.1%-0.8%+44.5%
Q1 2020-11.4%-8.8%+4.1%
Q1 2021-16.1%-22.2%-17.9%
Q4 2020+7.6%+29.9%+31.1%
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro